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Serotype-cross-reactive memory T cells responding to secondary dengue virus (DENV) infection are
thought to contribute to disease. However, epitope-specific T cell responses have not been thoroughly
compared between subjects with primary versus secondary DENV infection. We studied CD81 T cells
specific for the HLA-A*1101-restricted NS3133 epitope in a cohort of A111 DENV-infected patients
throughout acute illness and convalescence. We compared the expansion, serotype-cross-reactivity, and
activation of these cells in PBMC from patients experiencing primary or secondary infection and mild or
severe disease by flow cytometry. Our results show expansion and activation of DENV-specific CD81 T cells
during acute infection, which are predominantly serotype-cross-reactive regardless of DENV infection
history. These data confirm marked T cell activation and serotype-cross-reactivity during the febrile phase
of dengue; however, A11-NS3133-specific responses did not correlate with prior antigenic exposure or
current disease severity.
T
he four dengue virus serotypes (DENV1–4) have a significant and growing impact on global health. They are
responsible for over 38 million reported dengue cases each year with ,21,000 deaths1. Dengue disease
encompasses awide range of symptoms, usually presenting as an uncomplicated acute febrile illness (dengue
fever, DF); however, a small percentage of infections are associated with a plasma leakage syndrome (dengue
hemorrhagic fever, DHF), which can be life-threatening. Plasma leakage in DHF coincides with defervescence
and viral clearance2,3 suggesting that severe disease arises from the immune response rather than a direct viral
effect. In support of this, epidemiological studies indicate that severe dengue disease most often occurs during
secondary heterotypic DENV infection4–6.
Current hypotheses suggest that serotype-cross-reactive memory T cells reactivated in response to secondary
DENV infection mediate a sub-optimal immune response, contributing to dengue disease pathology7. Various
studies have explored the immunopathogenic role of cross-reactive memory T cells in DENV infection utilizing
blood samples from infected patients. A high percentage of DENV-specific T cells recognize multiple DENV
serotypes, as demonstrated by peptide-MHC (pMHC) tetramer binding and in vitro functional assays8–17.
Furthermore, patients with DHF have been shown to have greater T cell activation in vivo than patients with
DF, based on serum markers of activation18–22 or cell surface CD69 expression23. Few studies have reported a
higher frequency of DENV epitope-specific T cells in patients with DHF13,14,24, but other studies have questioned
the timing of T cell activation and its association with disease severity25,26. None of the previous reports have
compared responses to multiple serotypes in cohorts of dengue patients, distinguishing between primary and
secondary infection, in association with data on outcome of infection. In this study, we compared the expansion,
serotype-cross-reactivity, and activation of DENV-specific CD81 T cells in serial blood samples during acute
infection and convalescence in patients experiencing primary or secondary infection and mild or severe disease.
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Results
Dengue virus-specific CD81 T cells expand during acute
infection. We identified 44 HLA-A*11011 children experiencing
primary or secondary DENV infection (Table 1 and Supplementary
Table S1). We prepared pMHC tetramers using three peptide variants
of the previously defined A11-restricted NS3133–142 DENV epitope13,
corresponding to different DENV serotypes, with different
fluorochromes (Table 2). The specificity of each tetramer, and
conditions for simultaneous staining of cells, was demonstrated
using PBMC and epitope-specific T cell lines (Supplementary
Figure S1; see also ref 10). We stained PBMC from all time points
available for each subject with all three tetramers along with
antibodies to activation and phenotypic markers. Each experiment
included PBMC from a healthy, A111 DENV-naı¨ve subject as a
negative control and healthy PBMC spiked with an epitope-specific
T cell line as a tetramer-positive control. A positive cutoff value for
tetramer frequencies was defined as any frequency greater than that
measured for 11 of 12 A111 DENV-naı¨ve subjects (.0.14% of total
CD81 T cells equated to .92% specificity). Our flow cytometry
gating strategy is presented in Fig. 1a.
A11-NS3133 tetramer-positive CD81 T cells demonstrated clear
expansion and contraction from acute infection into convalescence
(Figure 1b and c and Supplementary Figure S2). Peak tetramer fre-
quencies could be defined in 36 of the 44 subjects (see Supplementary
Table S1). Of the remaining 8 subjects, 3 had data from one or no
sample during acute infection and 3 were missing data for one of the
tetramer variants; only 2 subjects with adequate data failed to show
an epitope-specific T cell response. Peak frequencies ranged from
0.15% to 19% of total CD81 T cells (median 5 0.75%, mean 5
2.33%). Dramatic changes in tetramer-positive T cell frequencies
between consecutive daily blood samples were observed in a few
subjects (Supplementary Figure S2); however, sample unavailability
precluded confirmation of these findings and we therefore interpret
these values with caution. Contraction of epitope-specific CD81 T
cells averaged 76% of the peak frequency at 1 year post-infection for
16 of 20 subjects with samples available. The remaining 4 subjects
had tetramer-positive T cell frequencies at 1–3 years post-infection
that were equal to or higher than the peak frequency during acute
infection. These subjects showed lower frequencies at 6months post-
infection; although there was no serologic evidence of reinfection in
these individuals we cannot exclude the possibility that these subjects
experienced another DENV infection.
Antigen-specific CD81 T cells are serotype-cross-reactive in both
primary and secondary dengue virus infection. We compared the
distribution of tetramer-positive T cells in subjects with primary
versus secondary DENV infection and with mild (DF) versus
severe (DHF) disease (Figure 2). The proportion of A11-NS3133-
specific T cells that bound tetramers specific for heterologous
DENV serotypes was similar in subjects with primary infection
compared to those with secondary infection. For example, at 1
week post-defervescence median frequencies of 77% and 65%
(p50.72) of epitope-specific T cells bound heterotypic tetramers
(those specific for serotypes other than the currently infecting
serotype) in primary and secondary infection, respectively. The
pattern of tetramer staining showed great sample-to-sample
variability, but, notably, it varied less across time points from the
same individual than between individuals. Despite the lack of clear
and consistent staining patterns according to the serotype of the
infecting virus or clinical diagnosis, we did note some similarities
among individuals within particular subject groups. For example,
subjects with primary DENV-3 infections had more pD21 cells
(shown in yellow) than subjects with secondary DENV-3
infections (median 5 15% versus 6% of epitope-specific T cells,
respectively; p50.02) or any DENV-1 infection (median 5 4%;
p50.002) at 1 week post-infection. In addition, subjects infected
with DENV-1 appeared to have a greater percentage of pD3/41
cells (shown in red) than those infected with DENV-3 at fever day
11, although the difference did not reach statistical significance
(median 5 30% versus 13% of epitope-specific T cells; p50.16). In
general, relatively few T cells bound to two or more tetramers at once
(shown in green, purple, orange and brown) and were more often
found in subjects with secondary infections (median 5 4% of
epitope-specific T cells for primary infections versus 12% for
secondary infections at 1 week, p50.03).
We detected preferential binding to the pD1 tetramer when T cells
were stained with the three A11-NS3133 tetramer variants. We
observed a similar staining pattern in peptide-stimulated short term
bulk cultures and epitope-specific T cell lines10. To evaluate the pos-
sibility that preferential binding to the pD1 tetramer was an artifact
of our staining conditions, we compared staining with all three tetra-
mer variants at once to staining with each variant individually
(Supplementary Figure S3a). Relative staining with individual tetra-
mer variants was consistent with staining detected when all three
tetramers were added together. To determine whether there was
competition for tetramer binding and if the concentration of tetra-
mer influenced the staining patterns, we stained T cell lines
with decreasing concentrations of the pD1 or pD3/4 tetramer while
Table 1 | Summary of HLA-A111 cohort information.
Serotypea Diagnosisb
Serology (no.)
Total (no.)Primary Secondary
DENV-1 DF 6 5 11
DHF 1 6 7
DENV-2 DF 2 2 4
DHF - 3 3
DENV-3 DF 5 4 9
DHF 3 6 9
DENV-4 DF - 1 1
DHF - - -
44
aOf current infection
bAccording to original WHO guidelines; DF 5 dengue fever, DHF 5 dengue hemorrhagic fever
Table 2 | Summary of epitope sequence information.
Epitope HLA restriction Serotype Sequence Designationa
DENV NS3133–142b A*1101 DENV-1 GTSGSPIVNR pD1
DENV-2 GTSGSPIVDR pD2
DENV-3, -4 GTSGSPIINR pD3/4
DENV NS3222–231c B*07 DENV-2, -3, -4 APTRVVAAEM B7-DENV
Influenza M158–66d A*0201 n/a GILGFVFTL A2-Flu
aAs used in this paper
bIdentified in ref 13
cIdentified in ref 41
dIdentified in refs 43 and 44
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 51 | DOI: 10.1038/srep00051 2
keeping the other tetramer concentrations constant. We observed no
increase in the frequency of cells that bound to the tetramer variants
kept constant (Supplementary Figure S3b). To determine whether
tetramer binding reflected functional responses, selected PBMC
samples obtained from several of the DENV-3 infected subjects in
early convalescence (within 1week of defervescence) were stimulated
ex vivo with each of the A11-NS3133 epitope variants in intracellular
cytokine staining assays. Cytokine production and/or degranulation
by CD81 T cells in response to heterologous epitope variants was
detected (Supplementary Figure S3c), consistent with our prior find-
ings of serotype-cross-reactive epitope-specific CD81 T cell lines
isolated from patients with primary DENV infection10.
We considered the possibility that the placement of gates could
have been inexact in delineating positive and negative tetramer stain-
ing and, thereby, our interpretation of serotype-cross-reactivity.
Quadrant gates were placed based on staining in positive and nega-
tive control specimens. For some subjects, pD1 tetramer-positive T
cells seemed to stain weakly with the pD3/4 tetramer, but did not
reach the threshold used to count as pD3/4 tetramer-positive
(pD113/41; refer to Figure 1b). To account for this, the intensity of
pD3/4 tetramer staining of all pD1 tetramer-positive CD81 T cells
was compared across all time points for subjects with primary versus
secondary DENV-3 infections (Supplementary Figure S3d). We
found no statistically significant differences between these subject
groups, further supporting our finding that the extent of serotype-
cross-reactivity did not differ according to DENV infection history.
Epitope-specific T cell frequencies peak earlier in primary than in
secondary dengue virus infection.We compared the kinetics of A11-
NS3133-specific T cell expansion in primary versus secondary
infection. We found that subjects undergoing primary infection
reached their peak tetramer frequency earlier in the course of illness
than those with secondary infection (p50.02; Table 3). Given the
more rapid proliferation of memory T cells, and the more rapid
clearance of viremia in secondary infection2, this result was not
anticipated. However, epitope-specific T cells down-regulated
CD45RA expression earlier in secondary infection than in primary
infection (Supplementary Figure S4). CD45RA is expressed on some
memory T cell populations27, as shown for A11-NS3133-specific T cells
in our cohort (Supplementary Figure S4). Therefore, earlier down-
regulation of CD45RA supports the reactivation of epitope-specific
memory T cells during secondary DENV infection. We did not
Figure 1 | A11-NS3133-specific T cells expand in acute dengue virus infection. a The gating strategy used to identify tetramer1CD81T cells selected cells
within a generous lymphocyte gate as defined by forward and side scatter profiles. Live cells were next selected by exclusion of the viability marker LIVE/
DEAD Aqua. T cells were identified by dual CD3 and CD8 expression followed by gating for singlet cells. b Representative flow plots of triple tetramer
staining of PBMC from a healthy HLA-A111 DENV-naı¨ve control donor (A111DENV-) as well as a HLA-A111 DENV-infected (A111DENV1)
individual over the course of acute illness and convalescence. The two rows of plots are different views of live, CD31CD81 singlet lymphocytes. c Box and
whisker plots show total tetramer-positive T cell frequencies in PBMC from subjects with primary (n516) or secondary (n523) DENV infection over
time. Days are relative to the day of defervescence (d0).
www.nature.com/scientificreports
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detect differences in the timing of peak tetramer frequency between
DF and DHF patients (data not shown).
The frequency of A11-NS3133-specific T cells does not correlate
with clinical findings. We tested whether the frequency of
A11-NS3133-specific T cells correlated with clinical diagnosis at days
0, 11 and 17 and found no significant differences (data not shown).
Therefore, we determined whether the peak frequency of epitope-
specific T cells, regardless of timing, correlated with clinical findings.
No statistically significant differences were found between subjects
Figure 2 | Tetramer-positive T cells are highly serotype-cross-reactive in subjects with primary or secondary infection. The distribution of sub-
populations within thewhole population of A11-NS3133 tetramer
1CD81T cells is depicted using pie charts. Tetramer-positive samples from subjects with
a (a–c) primary or (d–g) secondary infection with (a, d) DENV-1, (b, e) DENV-2, (c, f) DENV-3 or (g) DENV-4 are shown. No subjects with primary
DENV-4 infectionwere available. Each row represents data from a single donor over time. Time points shown are relative to the day of defervescence (d0),
d 5 day, w 5 week, m 5 month, y 5 year.
www.nature.com/scientificreports
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with DHF and those with DF (Figure 3a). However, among subjects
with DF, peak tetramer frequencies were slightly higher in secondary
infection than primary infection (p50.08), and among subjects with
secondary DENV infections, peak tetramer frequencies were slightly
higher in subjects with DF than those with DHF (p50.09). We also
found no correlations between peak tetramer frequencies and other
measures of disease severity, including pleural effusion index
(Figure 3b), aspartate aminotransferase values (Figure 3c), change in
hematocrit (Figure 3d), and platelet count (Figure 3e).
Antigen-specific CD81 T cells are highly activated during acute
dengue virus infection.We compared CD38 expression on antigen-
specific T cells in primary versus secondary infection according to
disease severity. High CD38 expression was seen in total CD81 T
cells and even higher expression in epitope-specific T cells was seen
during acute infection and shortly after defervescence (Figure 4a).
While levels of CD38 expression varied across individuals, the
averaged fluorescence intensity of tetramer-positive T cells in
PBMC from the four subject groups (primary DF, primary DHF,
secondary DF and secondary DHF) showed similar patterns over
time (Figure 4b).
T cell expansion in acute dengue virus infection is antigen-
specific. We considered that conclusions based on the analysis of a
singleDENV epitopemight not be generalizable or could reflect non-
specific rather than antigen-specific T cell expansion. Taking
advantage of previously identified epitopes for which we had
tetramers available, we identified a subset of A111 subjects that
were also HLA-A21 or HLA-B71. We stained samples from these
Table 3 | Tetramer frequencies peak earlier in primary DENV
infectiona.
No. subjects
Primary Secondary
Fever day #0b 4 1
Fever day 11 1 8d
Fever day 17c 1 6
aThis analysis only considers those subjects for whom we have blood samples from all three of these
time points (n521)
bOne primary subject had peak tetramer frequency at fever day -2
cThe actual day post-defervescence differs for each donor (range54–12, mean57)
dThe difference between fever days 0 and 11 is significant by Fisher’s exact test (p50.02)
Figure 3 | The magnitude of epitope-specific T cells does not correlate with disease severity. Peak A11-NS3133 tetramer1CD81 T cell frequencies are
plotted versus a clinical diagnosis (DF versus DHF), b pleural effusion index, c maximum aspartate aminotransferase (AST) value, d % change in
hematocrit, and e minimum platelet count. No significant correlations were detected by Mann-Whitney (a) or Spearman’s test (b–e).
www.nature.com/scientificreports
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subjects with the pD1 tetramer together with a tetramer specific for
either the B7-restrictedDENVNS3222–231 epitope (B7-DENV) or the
A201-restricted influenza virus M158–66 epitope (A2-Flu; refer to
Table 2).
Similar to pD1-specific T cells, B7-NS3222-specific CD81 T cells
expanded during acute infection, followed by a contraction phase in
late convalescence (Figure 5a). Frequencies of B7-DENV cells were
consistently higher than pD1-specific T cells in 4 of the 5 subjects
studied. A2-Flu M158-specific T cells were also present in a subset of
our patients, but their frequencies remained stable or decreased dur-
ing acute DENV infection. Although CD38 expression on A2-Flu
M158-specific T cells was slightly increased during acute DENV
infection, the average CD38 staining intensity on these cells was
lower than on DENV-specific T cells detected by either the A11-
NS3133 or B7-NS3222 tetramers (Figure 5b). These data demonstrate
selective activation and expansion of antigen-specific T cells during
acute DENV infection and imply that there was minimal contri-
bution of bystander cells to the T cell response to acute infection.
Discussion
Our results demonstrate similar frequencies of serotype-cross-react-
ive T cells ex vivo in naturally-infected patients with primary and
secondary DENV infections. T cell functional responses to hetero-
logous DENV epitopes were observed previously in some subjects
following primary DENV infections8,28, but this is the first demon-
stration of serotype-cross-reactivity in primary infection based on
binding of heterotypic tetramers ex vivo, and illustrates the breadth
of the phenomenon. Mongkolsapaya et al. found that A11-NS3133-
specific T cells in patients with secondary DENV infections preferen-
tially stained ex vivo with pMHC tetramers corresponding to DENV
serotypes heterologous to the infecting serotype13. We used a similar
approach, but extended our analysis to primary DENV infections, an
important comparison group absent in the earlier study. Preferential
binding to the pD1 tetramer (followed by the pD3/4 tetramer and,
finally, the pD2 tetramer) was also seen in our previous study of T cell
lines, which we postulated could be explained by their predicted
MHC binding (pD3/4$ pD1? pD2)10. Heterotypic tetramer bind-
ing for this epitope thus does not reflect the history of prior infection
with other DENV serotypes; other possible explanations for this
phenomenon are heterologous immunity from prior unrelated infec-
tions29, characteristics of the T cell repertoire30, or inherent immu-
nogenicity of different epitope variants8,31. It is possible that
preferential binding to the pD1 tetramer was a reflection of it being
the most stable of the three tetramers. However, this preferential
Figure 4 | Antigen-specific T cells are highly activated during acute DENV infection and early convalescence. a Representative histograms show the
expression of CD38 over time in total CD81 T cells from a healthy A111 donor (shaded) and an A111 DENV-infected donor (dark blue line) as well as
A11-NS3133 tetramer
1CD81 T cells from the same DENV-infected donor (light blue line). b The fold change in geometric mean fluorescence intensity
(gMFI) of CD38 staining in A11-NS3133 tetramer
1CD81 T cells from subjects with primary (solid lines) and secondary (dotted lines) DENV infections
with either DF (closed circles) or DHF (open squares) over time. Data are presented as means and are relative to the gMFI of CD38 of total CD81 T cells
from a healthy control donor included in each experiment.
www.nature.com/scientificreports
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binding would apply equally to the entire dataset, which would not
affect our ability to detect differences in the overall pattern of tetra-
mer staining between various subject groups. Despite donor-to-
donor variability, we did note some similarities in patterns of tetra-
mer staining among individuals with the same infection status
(DENV serotype, primary versus secondary). This suggests that the
sequence of infection does play a role in shaping the DENV-specific
memory T cell repertoire, although other factors are also important.
Mongkolsapaya et al. reported low but detectable frequencies of
A11-NS3133-specific T cells during acute secondary DENV infection
in Thai children which peaked in early convalescence13. In contrast,
Dung et al. reported that A11-NS3133-specific T cells were undetect-
able until after the development of plasma leakage among infected
Vietnamese children25. Our data (for both the A11-NS3133 and B7-
NS3222 epitopes) are clearly more consistent with the earlier report,
and, in fact, several of our subjects had very high frequencies of
(activated) epitope-specific T cells during acute infection. These
immune responses occurring prior to the onset of plasma leakage
therefore have the potential (i.e. are available) to contribute to disease
pathogenesis. The finding of antigen-specific T cell expansion and
activation during acute illness is also more consistent with observa-
tions in other viral diseases27,32,33 and with other evidence of T cell
activation during acuteDENV infection20,23,26. The divergent findings
of Dung et al. may reflect differences in experimental technique; a
more intriguing possibility is that the expansion of A11-NS3133-spe-
cific T cells might differ between Thai and Vietnamese patients. In
this regard, it is of interest that an association with dengue disease
severity has been observed forHLA-A11 in our Thai cohort34 but was
not noted in a study in Vietnam35 despite the similar genetic back-
grounds of these two populations.
We found that the frequency of epitope-specific T cells peaked
earlier in subjects with primary infection than in those with secondary
infection. Prior studies in which DENV-specific T cells were
tracked over time had not differentiated between subjects with
primary and secondary infections. Although this result was not
anticipated, it is consistent with findings in DENV infection of
BALB/c mice31. More rapid activation of memory T cells would
not necessarily correspond to an earlier peak T cell frequency,
since sustained proliferation signals balanced by apoptosis13,36
would affect the timing of peak responses to a greater extent.
Future studies need to incorporate analysis of these mechanisms
as well as other immunomodulatory signals such as regulatory
T cells37.
The magnitude of A11-NS3133-specific T cells did not correlate
with disease severity in this cohort. This held true whether the data
were analyzed according to clinical diagnosis (DF versus DHF) or
continuous measures of disease severity such as pleural effusion
index, hemoconcentration, or platelet nadir. A similar lack of asso-
ciation was reported in a study in Vietnam25. Other studies had
reported higher frequencies of DENV-specific T cells in patients with
DHF, but these associations were found at 2 weeks13,14 or 6 months24
post-infection.
The interpretation of our data is subject to several limitations.
Although our patient cohort was relatively large, the small number
of HLA-A111 subjects with the same DENV serotype, serologic res-
ponse (primary/secondary infection), and clinical outcome (DF/
DHF) limits the statistical power for important subgroup analyses,
and data fromHLA association studies suggest that the influence of T
cell responses may not be the same for all four serotypes34.
Additionally, although subjects were followed daily during acute
illness, adequate specimens were not available for all of these flow
cytometry studies from all time points for all subjects. Given that
rapid changes were observed in tetramer-positive T cell frequencies
during acute infection, it is likely that peak frequencies were missed
Figure 5 | T cell expansion and activation during dengue virus infection is antigen specific. a Box and whisker plots show the frequency of B7-NS3222
DENV epitope-specific or A2-M158 Flu epitope-specific T cells over the course of acute infection and convalescence in HLA-A11
1B71 (n55) or HLA-
A21A111 subjects (n56), respectively. b Themean fold change in gMFI of CD38 expression in pD11CD81T cells (blue), total CD81T cells (purple), and
B7-DENV1CD81 T cells (green) or A2-Flu1CD81 T cells (orange) relative to total CD81 T cells from healthy control donor PBMC (same donor used in
all experiments). Bars indicate standard deviation at each time point.
www.nature.com/scientificreports
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in some subjects. Furthermore, few of the DHF patients in our study
experienced shock (DHF grades 3 or 4). As Mongkolsapaya et al.
found the highest frequencies of tetramer-positive T cells in patients
with shock13,14, it is possible that the milder disease in our study
cohort concealed a relationship to the most severe disease.
Alternatively, we cannot exclude the possibility that the A11-
NS3133 epitope is not representative of the global DENV-specific
CD81 T cell response. Duangchinda et al. recently showed higher
cytokine responses in children with DHF compared to DF when
overlapping peptides covering the entire NS3 protein were used38.
However, that study only analyzed PBMC collected several weeks
post-infection and the same association was not detected by
Simmons et al.39. Finally, human studies are limited to analysis of
blood samples and we may have missed pathogenic T cells that were
bound to the endothelium or located in other tissues.
In summary, our data points to a complex picture of T cell
involvement in DENV infection. We found a selective activation
and expansion of DENV-specific T cells during acute infection and
a diverse pattern of serotype-cross-reactivity in both primary and
secondary infections. These findings will need to be taken into
account in future studies of T cell responses to natural DENV
infection and/or vaccines.
Methods
Study subjects and blood samples. The clinical study design and collection of blood
samples have been reported elsewhere3,40. Briefly, the study enrolled Thai children 6
months to 14 years of age with acute febrile illnesses. Acute DENV infections were
confirmed by serology and virus isolation/detection, and primary and secondary
infections were distinguished based on IgM5IgG ratio and hemagglutination-
inhibition antibody titer. Blood samples were obtained daily during acute illness, once
in early convalescence (,10 days after study entry) and at intervals during late
convalescence (6 months – 3 years after study entry), and PBMCwere cryopreserved.
Time points are reported relative to the day of defervescence (i.e. the day at which
fever dissipated and the patient subsequently maintained a temperature below 38uC),
which was termed fever day 0 (d0). Fever days -1, -2, etc. occurred before
defervescence, and day 11, etc. occurred after defervescence. Written informed
consent was obtained from each subject and/or his/her parent or guardian. The study
protocol was approved by the Institutional Review Boards of the Thai Ministry of
Public Health, the Office of the U.S. Army Surgeon General and the University of
Massachusetts Medical School. HLA typing was performed at the University of
Massachusetts Medical School or the Department of Transfusion Medicine, Siriraj
Hospital, as described34,41.
Peptide-MHC multimers. Peptides were purchased at.90% purity from AnaSpec,
Inc. (San Jose, CA, USA). Sequences are shown in Table 2. pMHC multimers (all
referred to as tetramers) were generated at the University of Massachusetts Medical
School Tetramer Core as described42. The different pMHC monomers were mixed
with their respective fluorochrome conjugates at molar ratios of 451 (A11-NS3133
epitope variants), 2551 (Flu M158 epitope) and 5051 (B7-NS3222 epitope). Tetramers
were conjugated to distinct fluorochromes to allow for staining with multiple
epitopes/variants simultaneously (APC-A11-NS3133-pD1, PE-Cy7-A11-NS3133-
pD2, PE-A11-NS3133-pD3/4, Qdot-605-A2-Flu M158, Qdot-605-B7-NS3222).
Staining and flow cytometry. Cryopreserved PBMC were thawed and rested in
RPMI/10% FBS at 37uC for approximately 2 hours. Cells were washed in PBS and
stained with LIVE/DEAD Aqua (Molecular Probes, Invitrogen Corp.) according to
the manufacturer’s instructions. Cells were washed and incubated with 0.5–2mL
tetramer for 20 minutes at 4uC. Monoclonal antibodies specific for CD3 (clone
UCHT1, Alexa Fluor 700 or clone SK7, PerCP-Cy5.5; BD Biosciences, San Jose, CA,
USA), CD8 (clone SK1, PerCP-Cy5.5 from BD Biosciences, clone 3B5, Qdot-655
from Invitrogen Corp., Carlsbad, CA, USA, or clone RAP-T8, Alexa Fluor 700 from
BD Biosciences), CD45RA (clone HI100, FITC; BD Biosciences), and CD38 (clone
HIT2 conjugated to Qdot-655 from Invitrogen Corp. or to PerCP-Cy5.5 from BD
Biosciences) were then added to the cells to incubate at 4uC for 30 minutes. Cells were
washed and fixed with BD Stabilizing Fixative (BD Biosciences). Data were collected
on a BD FACSAria and analyzed using FlowJo version 7.5.5.
Statistical analysis. For variables with a normal distribution, t-tests were used to
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